COVID-19 vaccine immunogenicity in people with HIV

A CITF-funded study, published in AIDS and led by Drs. Cecilia Costiniuk (McGill University) and Aslam Anis (University of British Columbia, found that vaccine-induced antibodies to SARS-CoV-2 were elicited in over 90% of people living with HIV (PLWS). Of those, most (92%), maintained those antibodies for six months following a second dose, although this percentage is less than it was for HIV-negative controls.